Last updated: 28 August 2024 at 4:18pm EST

Terry Kohler Net Worth




The estimated Net Worth of Terry Kohler is at least $246 Tisíc dollars as of 26 August 2024. Terry Kohler owns over 29,719 units of Verrica Pharmaceuticals Inc stock worth over $86,265 and over the last 3 years Terry sold VRCA stock worth over $160,134.

Terry Kohler VRCA stock SEC Form 4 insiders trading

Terry has made over 2 trades of the Verrica Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Terry sold 29,719 units of VRCA stock worth $77,567 on 26 August 2024.

The largest trade Terry's ever made was selling 29,719 units of Verrica Pharmaceuticals Inc stock on 26 August 2024 worth over $77,567. On average, Terry trades about 8,258 units every 41 days since 2021. As of 26 August 2024 Terry still owns at least 44,697 units of Verrica Pharmaceuticals Inc stock.

You can see the complete history of Terry Kohler stock trades at the bottom of the page.



What's Terry Kohler's mailing address?

Terry's mailing address filed with the SEC is C/O VERRICA PHARMACEUTICALS INC., 44 W. GAY ST., SUITE 400, WEST CHESTER, PA, 19380.

Insiders trading at Verrica Pharmaceuticals Inc

Over the last 6 years, insiders at Verrica Pharmaceuticals Inc have traded over $8,200,904 worth of Verrica Pharmaceuticals Inc stock and bought 11,305,854 units worth $62,586,502 . The most active insiders traders include Advisors Llcperceptive Life..., Paul B Manning a John A Iii Stalfort. On average, Verrica Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $213,456. The most recent stock trade was executed by Christopher G. Hayes on 26 August 2024, trading 35,713 units of VRCA stock currently worth $93,211.



What does Verrica Pharmaceuticals Inc do?

verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.



What does Verrica Pharmaceuticals Inc's logo look like?

Verrica Pharmaceuticals Inc logo

Complete history of Terry Kohler stock trades at Verrica Pharmaceuticals Inc

Dátum
#
Spoločnosť
Človek
Trans.
Transakcia
Počet akcií Cena za akciu Celková cena Počet akcií po Zdroj
26 Aug 2024 Terry Kohler
Finančný riaditeľ
Predaj 29,719 $2.61 $77,567
26 Aug 2024
44,697
14 Nov 2023 Terry Kohler
Finančný riaditeľ
Predaj 28,084 $2.94 $82,567
14 Nov 2023
34,416


Verrica Pharmaceuticals Inc executives and stock owners

Verrica Pharmaceuticals Inc executives and other stock owners filed with the SEC include: